https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
Marketing Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Marketing Team2022-12-20 12:04:442022-12-20 12:04:44IOnctura Awarded EUR17.5 Million Funding From The EIC Accelerator For Clinical Development Of Novel Pancreatic Cancer Therapy
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-20 07:57:072022-12-20 07:57:07Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD
https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos.png
180
300
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-15 15:06:052023-06-14 15:49:592022 | Optimum’s Year in Review
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-15 10:17:112022-12-15 10:17:11Cutting-edge protein design project to join BioInnovation Institute’s Bio Studio program
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-15 08:03:002022-12-15 08:03:00MinervaX announces 72M EUR financing to advance development of novel vaccine against Group B Streptococcus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-14 11:14:072022-12-14 11:14:07Alchemab Therapeutics | The Chain Podcast
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-14 09:27:102022-12-15 08:05:24Biocomposites announce a year of record sales and company growth
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
Marketing Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Marketing Team2022-12-14 08:38:182022-12-14 08:38:18ImaginAb Launches Phase II C-IT Neo Trial using CD8+ Cell Imaging to Investigate Neoadjuvant Immunotherapy
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-14 08:18:272022-12-14 08:18:27Poolbeg exclusively licences innovative oral delivery technology for metabolic syndrome related diseases
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-14 08:09:412022-12-14 08:09:41STORM Therapeutics announces closing of USD $30M Series B financing
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-13 08:10:522022-12-13 08:10:52Another Award for Synaffix: ‘Business Development Team of Year’ at the Scrip Awards
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-13 07:03:092022-12-13 07:03:09Futura Medical provide update on a milestone year of regulatory and commercial progress for MED3000
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-12 10:33:382022-12-12 10:33:38CellCentric presents early clinical data at ASH
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-12 08:02:192022-12-12 10:25:09Poolbeg Pharma plc. POLB 001 LPS human challenge clinical trial successfully completed. No serious adverse events reported. Results of full data analysis expected in Q2 2023
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
Marketing Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Marketing Team2022-12-07 09:03:062022-12-07 09:03:06Neuraxpharm expands into the Netherlands
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-06 08:35:532022-12-06 08:35:53ImaginAb Announces new Clinical Trial at Hull University Teaching Hospitals NHS Trust to Investigate CD8 ImmunoPET in Patients with Renal Cancer and Malignant Melanoma
https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos.png
180
300
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-12-01 15:49:362023-06-14 15:50:15LSX and Jefferies – Insights from the busiest week in European biotech
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-11-30 08:47:052022-11-30 08:47:05ISA Completes Enrolment in Randomized Double Blind Phase 2 Clinical Trial of ISA101b in HPV16 induced Oropharyngeal Cancer
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
LRuas
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
LRuas2022-11-30 08:46:422022-12-07 09:05:56NXI Therapeutics Expands Management Team and Board Ahead of Next Growth Stage
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
0
0
Marketing Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Marketing Team2022-11-29 09:27:572022-11-29 09:27:57Biocomposites adds Mexico to its list of countries where STIMULAN is approved as an antibiotic carrier for use in bone and soft tissueFor more information about Optimum Strategic Communications, please get in touch.
